MONTREAL, QUEBEC–(Marketwired – Oct. 10, 2017) – Pursuant to the early warning requirements of National Instrument 62-103, Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today an increase in its ownership of Crescita Therapeutics Inc. (“Crescita”).

On October 6, 2017, Knight acquired 566,471 common shares of Crescita, representing 4.0% of the issued and outstanding common shares of Crescita, pursuant to a share transfer agreement entered into on August 31, 2016 by and between Knight and Mr. Gregory Orleski (the “Agreement”). Pursuant to the Agreement, Knight was to receive additional shares of Crescita, for no consideration, based on the market price of Crescita’s shares on August 31, 2017. Knight now owns an aggregate of 2,079,973 common shares of Crescita representing approximately 14.9% of the outstanding common shares of Crescita. 

In addition, Knight holds 396,000 common share purchase warrants of Crescita, 216,000 of which are exercisable at a price of $0.75 per share and 180,000 at a price of $1.00 per share, in each case until August 14, 2023. Should Knight exercise the warrants, Knight would acquire an additional 396,000 common shares of Crescita, representing a 2.3% increase in Knight’s ownership of Crescita, after taking effect of the exercise of the warrants owned by Knight only.

The shares of Crescita acquired by Knight are held for investment purposes. Knight may in the future purchase or sell shares of Crescita or otherwise trade in securities of or engage in other transactions with respect to Crescita depending on a number of factors, including but not limited to, Crescita’s financial position, the price levels of the common shares of Crescita, conditions in the securities markets and general economic and industry conditions, Crescita’s business or financial condition, and other factors and conditions Knight deems appropriate.

For further information, a copy of the Early Warning Report to which this press release relates can be obtained from Jeffrey Kadanoff, (514) 484-4483 or on the SEDAR profile of Crescita at

“We are excited by Crescita’s potential and expect only GUD things to come from this investment,” said Jonathan Ross Goodman, CEO of Knight Therapeutics Inc.

About Crescita Therapeutics Inc.

Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases and their symptoms. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin. Crescita owns a portfolio of non-prescription skincare products and has one FDA approved prescription product, Pliaglis that is licensed globally to Galderma SA and Taro Pharmaceuticals for the U.S. market. Crescita owns the sales and marketing rights in Canada and Mexico. For additional information, please visit

About Knight Therapeutics Inc. 

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at or

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2016. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.